The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group
Open accessAbstract
BACKGROUND.: The objective of this study was to test a low dose of (25 mg weekly) of the mammalian target of rapamycin kinase inhibitor temsirolimus for patients with relapsed mantle cell lymphoma (MCL). METHODS.: Patients with relapsed or refractory MCL were eligible to receive temsirolimus 25 mg intravenously every week as a single agent. Patients who had a tumor response after 6 cycles were eligible to continue drug for a total of 12 cycles or 2 cycles after complete remission and then were observed without maintenance. RESULTS.: Of 29 enrolled patients, 28 were evaluable for toxicity, and 27 were evaluable for efficacy. The median age was 69 years (range, 51–85 years), 86% of patients had stage IV disease, and 71% had ≥2 extranodal sites. Patients had received a median of 4 prior therapies (range, 1–9 prior therapies), and 50% were refractory to the last treatment. The overall confirmed response rate was 41% (11 of 27 patients; 90% confidence interval [CI], 22%–61%) with 1 complete response (3.7%) and 10 partial responses (37%). The median time to progression in all eligible patients was 6 months (95% CI, 3–11 months), and the median duration of response for the 11 responders was 6 months (range, 1–26 months). Hematologic toxicities were the most common, with 50% (14 of 28 patients) grade 3 and 4% (1 of 28 patients) grade 4 toxicities observed. Thrombocytopenia was the most frequent cause of dose reduction. CONCLUSIONS.: Single‐agent temsirolimus at a dose of 25 mg weekly is an effective new agent for the treatment of MCL. The 25‐mg dose level retained the antitumor activity of the 250‐mg dose with less myelosuppression. Further studies of temsirolimus in combination with other active drugs for MCL and other lymphoid malignancies are warranted. Cancer 2008. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Cited by
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
Targeting the mTOR Signaling Network for Cancer Therapy
Meric-Bernstam, F., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0766 · Cited by 639
Dreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00667-4 · Cited by 463
Metadata
- Authors
- Ansell, S. M., Inwards, D. J., Rowland, K. M., Flynn, P. J., Morton, R. F., Moore, D. F., Kaufmann, S. H., Ghobrial, I., Kurtin, P. J., Maurer, M., Allmer, C., & Witzig, T. E.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-06-09
- Volume
- 113
- Issue
- 3
- Pages
- 508-514
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2077494567
- Cited by
- 203
- References
- 1
- FWCI
- 17.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group. https://app.cochat.ai/papers/10.1002/cncr.23580
- The paper
- Ansell, S. M., Inwards, D. J., Rowland, K. M., Flynn, P. J., Morton, R. F., Moore, D. F., Kaufmann, S. H., Ghobrial, I., Kurtin, P. J., Maurer, M., Allmer, C., & Witzig, T. E. (2008). Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group. Cancer. https://doi.org/10.1002/cncr.23580
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.